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Letters to the EditorSuccessful prevention of hepatitis C virus (HCV) liver graft
reinfection by silibinin mono-therapyTo the Editor:
Therapeutic measurements to control hepatitis C reinfection after
orthotopic liver transplantation (OLT) still pose many problems
and remain unsatisfactory [1]. While hepatitis C viremia
decreases strongly during the anhepatic phase of OLT, initiation
of viral replication does occur within hours or days [2,3]. At this
early stage after OLT, i.e. once chronic HCV reinfection is estab-
lished, the virologic response is often markedly reduced.
Although speciﬁcally targeted antiviral therapeutic regimes for
hepatitis C (STAT-C) are currently extensively studied, none of
them have been tried in the post-OLT period treatment.
However, as recently described by Ferenci et al. [4], high dose
intravenous silibinin (Legalon SIL) can express potent antiviral
activity. This effect was shown to be driven by direct inhibition
of the viral RNA polymerase NS5B [5,6].
In this letter, we can report the ﬁrst successful prevention of
HCV reinfection after OLT by the administration of silibinin
(1400 mg/d). This drug was applied immediately after OLT by
daily infusions for 14 days.
At the time of OLT, the 57-year-old male patient exhibited a
MELD Score of 23, Child-Pugh stage C liver cirrhosis, and a
25 mm hepatocellular carcinoma in the left lobe. HCV infection
(genotype 3a) was ﬁrst diagnosed in 1997 and three interferon-
based treatment regimens – at last PegInterferon alpha and Riba-
virin were given for 48 weeks 6 years before OLT – failed to
induce a sustained virologic response (SVR). The anhepatic phase
during OLT surgical procedures lasted 61 min and postoperative
care transpired without complication after a short phase of renal
insufﬁciency and haemodialysis treatment on day 1 and 2.
Immunosuppressive therapy included methyl-prednisolone,
mycophenolatmofetil, and belatacept. Aminotransferase levels
reached normal values within 12 postoperative days. Bilirubin
levels rose to a maximum of 9.5 mg/dl 7 days after OLT and
showed a protracted mild elevation until 4 weeks later. The
patient was discharged from the hospital 21 days after OLT.
The levels of HCV RNA 3 months prior to OLT were rather low
(17.800 IU/ml), and further declined signiﬁcantly during the
anhepatic phase. Silibinin infusions were started 8 h after OLT.
At this time HCV RNA levels measured 182 IU/ml, and dropped
again to 127 IU/ml after 48 h (RNA levels measured directly after
haemodialysis are not available). Already from day 3 onwards,
HCV RNA levels were below <15 IU/ml and became undetectable
at day 9. During follow-up HCV RNA remained negative when
examined at day 14, 21, 66, 84, and 168 (Fig. 1).
This is the ﬁrst report of the successful suppression of early
HCV reinfection after OLT with a 14 day course of silibinin
mono-therapy. This new treatment regimen thus induced an
SVR, as after 6 months of follow-up, RNA for HCV was undetect-
able. Accordingly, liver histology 6 months after OLT did not
show any cellular inﬂammation. Low pre-transplant HCV RNAJournal of Hepatologylevels may be taken as a favourable prognostic factor for the
unexpected therapeutic efﬁciency of silibinin. Applying silibinin
during the anhepatic phase or even in the days before transplant
may expand the number of patients beneﬁting from this
approach. This report may stimulate further trials and the con-
cept of interferon-free HCV clearance induced by direct
antivirals.
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Combination of acarbose and ezetimibe prevents non-alcoholic
fatty liver disease: A break of intestinal insulin resistance?
To the Editor:
We readwith great interest the study by Nozaki and colleagues
[1] that evaluated the effect of combination therapy of ezetimibe,
an intestinal cholesterol adsorption inhibitor, and acarbose, an
alpha glucosidase inhibitor, on the prevention of the high-fat diet
induced, non-alcoholic fatty liver disease (NAFLD) inmice. In their
study, the authors concluded that the combination of both drugs
for 24 weeks signiﬁcantly reduced steatosis, inﬂammation, and
ﬁbrosis in the liver of animals, compared to long-term mono-
therapy with either drug. Insulin resistance and liver steatosis
are interlinked metabolic abnormalities, whose prevalence is rap-
idly increasing worldwide [2]. We absolutely agree that the effec-
tive pharmacological therapy for prevention or treatment of
NAFLD does not exist today, and we thus acknowledge that the
recent study by Nozaki and colleagues has paved the way towards
a new therapeutic approach for the prevention and treatment of
NAFLD. However, we have some concerns regarding this study
and its conclusions, which are outlined as follows:
The authors use the high-fat diet which contains more than
57% of calories from fat and only 22.8% of carbohydrates to
induce the NAFLD in animals. Despite the importance of impair-
ment in the lipid metabolism and quantity of the dietary fat
intake for the development of NAFLD [2], the high carbohydrate
intake is also involved in the pathogens of NAFLD: ﬁrst, the ‘‘soft
drinks” without fat content were associated with hepatic steato-
sis independent of insulin resistance in humans [3]; second, die-
tary habits with high glycemic index were associated with liver
steatosis [4]. Thus, the additional model using the high glycemic
load were of interest for such experimental design. Another point
is the action of the acarbose in the studied dietary conditions: the
strong reduction of carbohydrate intake led to the diminished
action of acarbose and promising effects for ezetimibe. Interest-
ingly and surprisingly, the reduction of fasting glycemia and insu-
linemia under ezetimibe treatment was as pronounced as the
effects of the antidiabetic drug acarbose. Based on the principal
postprandial actions of both drugs, the data from oral stimulation
tests, such as oral glucose loading or meal test, could be of great
interest regarding the mechanisms of NAFLD prevention.
The major and very intriguing observation is the effect of the
combination of acarbose and ezetimibe during the progression of
NAFLD in the high-fat diet. The authors concluded two hypotheses
in order to explain the observed effects: (i) the additive ormultipli-
cative effects of both drugs on cholesterol reduction accompanying
the inhibition of gut glucose absorption lead to the improvement of
systemic insulin sensitivity and/or (ii) the promotion of lipid dis-
charge from the liver and the b-oxidation of lipids in the liver.
Regarding the ﬁrst hypothesis, after a 12-week high-dose acar-
bose treatment (300 mg/d), our data in humans showed no effects
on whole body insulin sensitivity, measured in the euglycemic
clamp, and no changes in body weight [5]. Moreover, we observed
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Fig. 1. Effect of intravenous silibinin administration on the course of hepatitis C viremia (upper panel) and aminotransferase (ALT) and bilirubin levels (lower
panel) after liver transplantation. HCV RNA levels were measured by real-time PCR assay (Cobas AmpliPrep Taqman, Roche Diagnostics, Germany); ALT and bilirubin
levels are depicted as relative values of the upper limit of normal (ULN).
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